• Crizotinib: New Standard for ALK+ Myofibroblastic Tumor

    4 days ago - By Medscape

    With 100% disease control rates in patients with ALK+ inflammatory myofibroblastic tumor - a very rare type of soft tissue sarcoma - crizotinib should be the standard of care, say experts.
    Medscape Medical News
    Read more ...